Anti-vascular endothelial growth factor and macular atrophy: an unanswered question

Does anti-vascular endothelial growth factor (VEGF) therapy lead to geographic atrophy? If so, does the number of injections or the duration of anti-VEGF therapy correlate with the risk of developing geographic atrophy? With intravitreal injections becoming the most common ophthalmic invasive procedure and an increasingly aging population, these questions really matter.